Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade

Treatments aiming to augment immune checkpoint blockade (ICB) in cancer often focus on T cell immunity, but innate immune cells may have important roles to play. Here, we demonstrate a single-dose combination treatment (termed AIP) using a pan-tumor-targeting antibody surrogate, half-life-extended i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chensu, Cui, Ang, Bukenya, Maurice, Aung, Aereas, Pradhan, Dikshant, Whittaker, Charles A., Agarwal, Yash, Thomas, Ayush, Liang, Simon, Amlashi, Parastoo, Suh, Heikyung, Spranger, Stefani, Hacohen, Nir, Irvine, Darrell J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653865/
https://www.ncbi.nlm.nih.gov/pubmed/34818534
http://dx.doi.org/10.1016/j.celrep.2021.110021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653865/
https://www.ncbi.nlm.nih.gov/pubmed/34818534
http://dx.doi.org/10.1016/j.celrep.2021.110021

Ejemplares similares